How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,348 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

to Prevent ETEC Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01644565 Recruitment Status : Unknown Verified October 2015 by U.S. Army Medical Research and Materiel Command. Recruitment status was: Active, not recruiting First Posted : July 19, 2012 Last Update Posted : November 2, 2015 Sponsor (...) Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study of Chimeric Vaccine

2012 Clinical Trials

142. Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy

/severe (grade 2-4) diarrhea graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. II. Functional Assessment of Chronic Illness Therapy - Diarrhea (FACIT-D) Trial Outcome Index. SECONDARY OBJECTIVES: I. To evaluate the effects of probiotic supplementation on dose delays or reductions due to gastrointestinal (GI) toxicity. II. To evaluate the effects of probiotic supplementation on anti-diarrheal medication use. III. To evaluate the effects of probiotic supplementation (...) and conventional cytotoxic chemotherapy will be analyzed both combined and separately. FACIT-D Trial Outcome Index (TOI) [ Time Frame: Up to 4 weeks post treatment ] The FACIT-D TOI has a range of scores from 0-100 which are a combination of physical well being, functional well being, and diarrhea subscale. The data for patients on tyrosine kinase inhibitors and conventional cytotoxic chemotherapy will be analyzed both combined and separately. Secondary Outcome Measures : Dose delays or reductions due to GI

2012 Clinical Trials

143. Acute Diarrhea

, Diarrhea , Acute Infectious Diarrhea , Infectious Diarrhea , Bacterial Diarrhea From Related Chapters II. Definition Inflammation of the gastrointestinal tract ( e and ) Typical presentation is followed by Diarrhea Most typically secondary to Can also be caused by with ingestion of preformed toxin Diarrhea Frequent liquid stools Adults: >200 g/day of stool (at least 3 s daily) Children: >20 g/kg/day of stool Timing Acute Diarrhea: Duration <2 weeks : Duration >4 weeks III. Epidemiology Foodbourne (...) es (30-40% of episodes) (90% of non- l diarhea) and s (20-30% of episodes) Inflammatory Diarrhea from and s (most common ) Shiga-toxin producing (e.g. :H7, ) Causes 30% of infectious bloody Diarrhea Non-inflammatory Diarrhea from and s Bacillus cereus VII. Risk Factors See for systemic medical condition causes of Diarrhea See Recent travel to endemic area See Travel to a developing area is associated with a 25% chance of developing Diarrhea Those with Diarrhea in a developing area have an 80

2015 FP Notebook

144. Diarrhea in HIV

) These images are a random sampling from a Bing search on the term "Diarrhea in HIV." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Diarrhea About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Diarrhea in HIV Diarrhea in HIV Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea in HIV Diarrhea in HIV Aka: Diarrhea in HIV

2015 FP Notebook

145. Antibiotic Associated Diarrhea

Diarrhea Antibiotic Associated Diarrhea Aka: Antibiotic Associated Diarrhea , Diarrhea Secondary to Antibiotic Use , Antibiotic-Associated Diarrhea From Related Chapters II. Precautions Antibiotics in the emergency department frequently cause IV antibiotics: 26% of cases Oral antibiotics: 12% of cases , and antibiotic combinations were highest risk for Reconsider whether antibiotics are indicated and if so, if IV route is needed Oral bioavailability of most antibiotics is excellent Single dose IV (...) antibiotics prior to home oral antibiotics is rarely indicated References Arora and Menchine in Herbert (2015) EM:Rap 15(1): 11 III. Causes: Bacterial Overgrowth Syndromes secondary to antibiotics oxytoca Responds to stopping antibiotics (and possibly to stopping s) IV. Prevention: Probiotics Efficacy (NNT): 13 Treating 13 patients prevents one case of Antibiotic Associated Diarrhea Live-culture yogurt reduces due to antibiotics Lactobacillus acidophilus Lactobacillus bulgaricus thermophilus Other

2015 FP Notebook

146. Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

to Prevent ETEC Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01382095 Recruitment Status : Completed First Posted : June 27, 2011 Last Update Posted : April 27, 2015 Sponsor: U.S. Army Medical Research and Materiel Command Information provided by (Responsible Party): U.S. Army Medical Research (...) Reed Army Institute of Research ) First Posted: June 27, 2011 Last Update Posted: April 27, 2015 Last Verified: April 2015 Keywords provided by U.S. Army Medical Research and Materiel Command: ETEC Diarrhea Vaccine Additional relevant MeSH terms: Layout table for MeSH terms Escherichia coli Infections Enterobacteriaceae Infections Gram-Negative Bacterial Infections Bacterial Infections

2011 Clinical Trials

147. Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

Patients who drink over 2oz alcohol/day on a regular basis Any other causes for diarrhea such as IBD, microscopic colitis, celiac disease, history of abdominal obstruction, pancreatitis, ileus, or any gastrointestinal bleeding. Patients with active malignancy in the past five years Patient with any history of hypersensitivity reactions to salicylate containing medications due to cross-sensitivity with mesalamine or allergy to mesalamine medications in the past Any subjects with fibromyalgia (...) Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2011 Clinical Trials

148. Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults

Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01302093 Recruitment Status : Completed First Posted : February 23, 2011 Last Update Posted : July 10

2011 Clinical Trials

149. Zinc Supplementation and Severe and Recurrent Diarrhea

Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01306097 Recruitment Status : Completed First Posted : March 1, 2011 Last Update Posted : March 1, 2011 Sponsor: Hormozgan University of Medical Sciences Information provided by: Hormozgan University of Medical Sciences Study Details Study (...) : 1 years ] Incidence, Duration and frequency Secondary Outcome Measures : Admission for diarrhea [ Time Frame: 1 year ] Total number of admissions during the study period Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using

2011 Clinical Trials

150. Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea

adding more. Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01269892 Recruitment Status : Completed First Posted : January 4, 2011 Last Update Posted : January 4, 2011 Sponsor: Isfahan University of Medical Sciences (...) Information provided by: Isfahan University of Medical Sciences Study Details Study Description Go to Brief Summary: The purpose of this study is to determine which nutritional regime is better for acute diarrhea in outcomes. Condition or disease Intervention/treatment Phase Acute Diarrhea Dietary Supplement: lactose-free milk Dietary Supplement: conventional milk Phase 2 Detailed Description: Diarrhea is still the most important cause of mortality and morbidity in children of the developing countries. We

2011 Clinical Trials

151. Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea

Sponsor: Kyunghee University Medical Center Information provided by (Responsible Party): Seok-Jae Ko, Kyunghee University Medical Center Study Details Study Description Go to Brief Summary: The aims of this study are to investigate the effect of famous herbal formula extract and probiotics on irritable bowel syndrome with diarrhea, and to determine whether these two experimental items affect intestinal permeability and the composition of intestinal microbiota. Condition or disease Intervention (...) : June 5, 2012 Last Verified: June 2012 Keywords provided by Seok-Jae Ko, Kyunghee University Medical Center: Irritable bowel syndrome Herbal medicine Probiotics Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases

2011 Clinical Trials

152. Prevention of Irinotecan Induced Diarrhea by Probiotics

cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle. Outcome Measures Go to Primary Outcome Measures : Prevention of grade 3-4 diarrhea by probiotics in patients treated by irinotecan based chemotherapy [ Time Frame: 2 years ] Secondary Outcome Measures : Prevention of any grade of diarrhea [ Time Frame: 2 years ] Number of patients with any grade 3 or 4 toxicity or SAE related toxicity. [ Time Frame: 2 years ] Number of patients (...) Prevention of Irinotecan Induced Diarrhea by Probiotics Prevention of Irinotecan Induced Diarrhea by Probiotics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prevention of Irinotecan Induced Diarrhea

2011 Clinical Trials

153. Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children

in patients ingesting L. reuteri versus placebo during the study period, measured as mean number of episodes per patient. An episode of diarrhea is defined as three or more (≥ 3) soft and unformed or watery bowel movements per day for at least 48 hours. Secondary Outcome Measures : Incidence of mild diarrhea and severity if diarrhea in children with probiotic treatment [ Time Frame: 2 years ] Incidence of mild diarrhoea during and after treatment with antibiotics in patients ingesting L. reuteri versus (...) Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2011 Clinical Trials

154. Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital

Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital (infloran) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01273012 Recruitment Status : Unknown Verified July 2011 by Phramongkutklao College of Medicine

2011 Clinical Trials

155. Influence of Carob and Probiotics on Acute Diarrhea in Children

and Probiotics on Acute Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01501305 Recruitment Status : Unknown Verified December 2011 by Hillel Yaffe Medical Center. Recruitment status was: Not yet recruiting First Posted : December 29, 2011 Last Update Posted : December 29, 2011 Sponsor (...) : Hillel Yaffe Medical Center Information provided by (Responsible Party): Hillel Yaffe Medical Center Study Details Study Description Go to Brief Summary: Comparison of Carob powder with probiotics vs oral hydration solution in diarrhea treatment in children. Condition or disease Intervention/treatment Phase Diarrhea Dietary Supplement: Mineral solution Dietary Supplement: Carob powder with probiotics Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional

2011 Clinical Trials

156. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01494233

2011 Clinical Trials

157. The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

will be allowed during the study Receipt of influenza vaccination will be allowed prior, during, and/or after the study Use of topical medications that are not significantly absorbed systemically will be allowed if approved by the Principal Investigator Inability to obtain venous access for sample collection. Inability to swallow whole capsules and/or tablets. Positive serum or urine pregnancy test or breastfeeding female. The presence of persistent diarrhea or malabsorption that could interferewith (...) The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

158. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly 1 AACE Guidelines Laurence Katznelson, MD; John L. D. Atkinson, MD; David M. Cook, MD, FACE; Shereen Z. Ezzat, MD, FRCPC; Amir H. Hamrahian, MD, FACE; Karen K. Miller, MD American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision (...) making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may

2011 American Association of Clinical Endocrinologists

159. Risk Factors for Crohn's Disease of the Neo-Small Intestine in Ulcerative Colitis Patients with Total Proctocolectomy and Primary or Secondary Ileostomies. (PubMed)

trying of ileal pouch) and secondary ileostomy (SI, i.e., stoma created after pouch failure) and to evaluate factors associated with the development of CD of the neo-small intestine proximal to ileostomy.A total of 123 eligible patients were identified from our Pouch Center Registry (PI group, n = 57 and SI group, n = 66). Demographics, clinical features and outcomes (CD of theneo-small intestine, non-CD related strictures, requirement of CD-related medications use, ileostomy-associated (...) Risk Factors for Crohn's Disease of the Neo-Small Intestine in Ulcerative Colitis Patients with Total Proctocolectomy and Primary or Secondary Ileostomies. De novo Crohn’s disease (CD) of the neo-small intestine in ulcerative colitis (UC) patients after total proctocolectomy (TPC) is a new disease entity, which may persist even after a secondary diverting permanent ileostomy for pouch failure. We sought to compare outcomes of primary ileostomy (PI, i.e., stoma created after colectomy without

Full Text available with Trip Pro

2014 Journal of Crohn's & colitis

160. Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic – Induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MScPhm, ACPR, FCSHP Sabrina Boodhan BScPhm, ACPR Lillian Sung MD, PhD Carol Portwine MD, FRCPC, PhD Richard Hain MD Patricia McCarthy RN, (EC), MSc(A) Mark (...) and the expert consensus of the POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Group, the following classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients is recommended: Recommendation: The single antineoplastic agents provided in Table 1 have high, moderate, low or minimal emetogenic potential in children. Table 1: Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Given

2010 SickKids Supportive Care Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>